DocGo (DCGO) AI Stock Analysis

• Market Cap: $104.65M
• Dividend Yield: N/A
• Average Volume (3M): 2.56M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.98
• Revenue Growth: -41.31%
• EPS Growth: -163.08%
• Country: US
• Employees: 3,404
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): -0.11
• Shares Outstanding: 97,808,136
• 10 Day Avg. Volume: 1,423,681
• 30 Day Avg. Volume: 2,558,091
• PEG Ratio: 0.11
• Price to Book (P/B): 1.35
• Price to Sales (P/S): 0.70
• P/FCF Ratio: 6.73
• Enterprise Value/Market Cap: 0.98
• Enterprise Value/Revenue: 0.23
• Enterprise Value/Gross Profit: 0.70
• Enterprise Value/Ebitda: -7.88
• 1Y Price Target: $3.15
• Price Target Upside: 183.78% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: $1.00 ▼(-9.91% Downside)

DocGo's overall stock score reflects significant financial challenges, with declining revenue and profitability, and bearish technical indicators. While the earnings call provided some positive insights, such as improved cash flow and cost reductions, these are overshadowed by the negative revenue trend and valuation concerns.

Positive Factors

Cash Flow Improvement

Improved cash flow from operations enhances financial stability and provides the company with more resources to invest in growth opportunities.

Acquisition of SteadyMD

The acquisition of SteadyMD expands DocGo's telehealth capabilities and market reach, potentially increasing revenue and enhancing competitive positioning.

SG&A Cost Reductions

Reducing SG&A costs improves operational efficiency, contributing to better profitability and enabling the company to allocate resources more effectively.

Negative Factors

Revenue Decline

A significant decline in revenue indicates challenges in maintaining market demand and could impact long-term growth prospects if not addressed.

Negative EBITDA

Negative EBITDA reflects operational inefficiencies and margin pressures, which may hinder the company's ability to achieve sustainable profitability.

Declining Profitability

Decreasing profitability suggests challenges in cost management and revenue generation, potentially affecting long-term financial health and investor confidence.

DocGo Business Overview & Revenue Model

Company Description

DocGo, Inc. provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services. It also offers mobile health services through its platform that are performed at home and offices; COVID-19 testing; and event services, which include on-site healthcare support at sporting events and concerts. DocGo, Inc. was incorporated in 2015 and is headquartered in New York, New York.

How the Company Makes Money

DocGo generates revenue through multiple channels, primarily by billing for its healthcare services provided to patients and healthcare facilities. Key revenue streams include direct payments from patients for telehealth consultations, contracts with hospitals and clinics for on-site medical services, and partnerships with healthcare organizations to provide mobile health solutions. Additionally, the company may receive reimbursements from insurance providers for covered services. Significant partnerships with hospitals and health systems enhance its service offerings and expand its market reach, contributing to overall revenue growth.

DocGo Financial Statement Overview

Summary

DocGo faces significant challenges in maintaining stable financial performance. The income statement shows declining revenue and profitability, while the balance sheet reflects moderate leverage but poor returns on equity. Cash flow generation is inconsistent, highlighting the need for improved operational efficiency and financial management.

Income Statement

DocGo's income statement shows significant volatility. The TTM data indicates a negative revenue growth rate of -16.24%, and negative margins across the board, with a net profit margin of -4.20%. Historical data shows fluctuating revenue growth and profitability, with a notable decline in recent periods. The company faces challenges in maintaining stable revenue and profitability.

Balance Sheet

The balance sheet reflects a moderate debt-to-equity ratio of 0.20 in the TTM period, indicating manageable leverage. However, the return on equity is negative, suggesting inefficiencies in generating returns from equity. The equity ratio is relatively stable, but the company needs to improve its profitability to enhance balance sheet strength.

Cash Flow

Cash flow analysis reveals a mixed picture. The TTM free cash flow growth is exceptionally high at 48718800.06%, but this is likely due to a low base effect. The operating cash flow to net income ratio is 0.43, indicating some challenges in converting income to cash. The company needs to stabilize its cash flow generation to support operations and growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	435.97M	616.56M	624.29M	440.52M	318.72M	94.09M
Gross Profit	146.69M	213.57M	195.38M	154.72M	109.75M	31.35M
EBITDA	-12.95M	45.56M	31.49M	32.40M	28.07M	-9.25M
Net Income	-18.33M	19.99M	6.86M	34.58M	23.74M	-14.36M
Balance Sheet
Total Assets	408.26M	455.62M	490.45M	393.28M	309.60M	100.17M
Cash, Cash Equivalents and Short-Term Investments	104.16M	89.24M	59.29M	157.34M	175.54M	32.42M
Total Debt	60.45M	57.19M	46.50M	19.91M	16.51M	13.89M
Total Liabilities	120.53M	140.44M	185.28M	114.35M	82.55M	33.23M
Stockholders Equity	297.28M	320.92M	300.79M	273.23M	219.58M	55.00M
Cash Flow
Free Cash Flow	81.32M	64.50M	-74.35M	23.37M	-8.60M	-16.97M
Operating Cash Flow	87.18M	70.34M	-64.22M	28.87M	-1.95M	-10.65M
Investing Cash Flow	-34.19M	-10.87M	-29.88M	-38.45M	-8.59M	-6.04M
Financing Cash Flow	-31.11M	-24.15M	1.12M	-6.18M	155.21M	-812.09K

DocGo Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.11
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DCGO, the sentiment is Negative. The current price of 1.11 is below the 20-day moving average (MA) of 1.17, below the 50-day MA of 1.33, and below the 200-day MA of 2.14, indicating a bearish trend. The MACD of -0.08 indicates Negative momentum. The RSI at 43.83 is Neutral, neither overbought nor oversold. The STOCH value of 38.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DCGO.

DocGo Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TALK	61 Neutral	$567.71M	139.75	3.74%	―	18.37%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DCGO	50 Neutral	$104.65M	―	-5.98%	―	-41.31%	-163.08%
AMN	50 Neutral	$706.32M	―	-35.90%	―	-11.42%	-617.31%
BTMD	49 Neutral	$144.86M	3.59	―	―	1.34%	185.03%
AGL	42 Neutral	$289.05M	―	-73.31%	―	5.21%	5.21%
PIII	40 Underperform	$60.81M	-0.17	-138.17%	―	4.20%	-54.16%

DocGo Corporate Events

DocGo Acquires SteadyMD to Expand Telehealth Services

On October 20, 2025, DocGo Inc. announced the acquisition of SteadyMD, a virtual care platform, for up to $25 million. This strategic move combines DocGo’s mobile health services with SteadyMD’s telehealth capabilities, expanding their reach across all 50 states and enhancing their ability to deliver efficient patient care. The acquisition is expected to generate approximately $25 million in revenue for SteadyMD in 2025, with plans to update financial guidance in upcoming earnings releases. This acquisition marks a significant step in DocGo’s mission to provide comprehensive last-mile healthcare solutions and improve access and outcomes for patients.

The most recent analyst rating on (DCGO) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on DocGo stock, see the DCGO Stock Forecast page.

DocGo, Inc. Earnings Call: A Mixed Bag of Progress and Challenges

DocGo, Inc.’s recent earnings call presented a mixed sentiment, highlighting both achievements and challenges. The company reported strong operational cash flow and significant reductions in accounts receivable, demonstrating robust financial management. However, these positives were tempered by challenges such as a decline in overall revenue and adjusted EBITDA losses, primarily due to the wind-down of migrant-related programs.

DocGo Reports Q2 2025 Results Amid Revenue Decline

DocGo, Inc. is a prominent player in the healthcare sector, specializing in technology-enabled mobile health and medical transportation services. The company aims to revolutionize traditional healthcare delivery by offering high-quality, accessible care through its innovative platform.